

Cardiovascular (CV) Outcome Trials: SGLT2

Adapted from Cardiac benefits in Diabetes Therapy: Comparing SGLT2 Inhibitors and GLP-1 Agonists

By Samuel Grossman, BS Pharm, PharmD, CDE, FADE

Name of trial	Patient	Groups	Outcomes: ASCVD	Outcomes: HF
EMPA-REG OUTCOME	7020 with CV	Empagliflozin vs. placebo	significant reduction in MI, stroke, CV death vs. placebo	Significant (35%) reduction in hospitalization for HF vs. placebo
CANVAS CANVAS-Renal *DECLARE ¹	10,142 with CV 4401 with albuminuric kidney disease	Canagliflozin vs. placebo	Significant reduction in MI, stroke, CV death vs. placebo	Significant (33%) reduction in hospitalization for HF. Increased risk for lower-limb amputation vs. placebo *significantly lower Death from renal causes, hospitalization for HF, vs. placebo

HF: Heart Failure

References:

- Diabetes Care 2019;42 (suppl. 1):s115-s119
- http://www.onlinejacc.org/content/accj/73/9_Supplement_1/1.full.pdf accessed 9/19
- <https://www.nejm.org/doi/full/10.1056/NEJMoa1811744> accessed 9/19 1